Bevacizumab in Metastatic Renal Cancer

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a non-interventional, multicenter study to evaluate efficacy and safety of intravenous bevacizumab (Avastin) in combination with interferon alpha-2a immunotherapy for first-line treatment in participants with advanced and/or metastatic renal cell cancer (mRCC) in daily routine.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Bevacizumab; Interferon alpha-2; Interferon-alpha; Interferons

Criteria

Inclusion Criteria:

• Histologically confirmed advanced and/or metastatic renal cell cancer

• No contraindications for Avastin according to summary of product characteristics (SmPC)

Exclusion Criteria:

-